NEW YORK, NY / ACCESSWIRE / June 8, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

PTON Shareholders Click Here: https://www.zlk.com/pslra-1/peloton-interactive-inc-loss-submission-form?prid=16713&wire=1
ATER Shareholders Click Here: https://www.zlk.com/pslra-1/aterian-inc-loss-submission-form?prid=16713&wire=1
FREQ Shareholders Click Here: https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=16713&wire=1

* ADDITIONAL INFORMATION BELOW *

Peloton Interactive, Inc. (NASDAQ:PTON)

PTON Lawsuit on behalf of: investors who purchased September 11, 2020 - May 5, 2021
Lead Plaintiff Deadline : June 28, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/peloton-interactive-inc-loss-submission-form?prid=16713&wire=1

According to the filed complaint, during the class period, Peloton Interactive, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) in addition to the tragic death of a child, Peloton's Tread+ had caused a serious safety threat to children and pets as there were multiple incidents of injury to both; (2) safety was not a priority to Peloton as defendants were aware of serious injuries and death resulting from the Tread+, yet did not recall or suggest a halt of the use of the Tread+; (3) as a result of the safety concerns, the U.S. Consumer Product Safety Commission ("CPSC") declared that the Tread+ posed a serious risk to public health and safety and urgently recommended that consumers with small children cease using the Tread+; (4) the CPSC also found a safety threat to Tread+ users if they lost their balance; and (5) as a result of the foregoing, defendants' statements about Peloton's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Aterian, Inc. (NASDAQ:ATER)

ATER Lawsuit on behalf of: investors who purchased December 1, 2020 - May 3, 2021
Lead Plaintiff Deadline: July 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/aterian-inc-loss-submission-form?prid=16713&wire=1

According to the filed complaint, during the class period, Aterian, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's organic growth is plummeting; (ii) the Company's recent, self-lauded acquisitions were overpayments for flawed assets from questionable sources; (iii) Aterian's purported artificial intelligence software is a flawed product that lacks customer interest; (iv) Aterian uses rebate programs and paid or artificial reviews to pump up their product offerings; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Frequency Therapeutics, Inc. (NASDAQ:FREQ)

FREQ Lawsuit on behalf of: investors who purchased November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline : August 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=16713&wire=1

According to the filed complaint, during the class period, Frequency Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

View source version on accesswire.com:
https://www.accesswire.com/651027/CLASS-ACTION-UPDATE-for-PTON-ATER-and-FREQ-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders